Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Jul 18, 2023

SELL
$3.21 - $5.06 $69,994 - $110,333
-21,805 Reduced 91.94%
1,911 $7,000
Q1 2023

Apr 13, 2023

BUY
$3.0 - $4.97 $61,263 - $101,492
20,421 Added 619.76%
23,716 $79,000
Q4 2022

Jan 23, 2023

SELL
$4.35 - $6.17 $34,678 - $49,187
-7,972 Reduced 70.76%
3,295 $0
Q3 2022

Oct 26, 2022

BUY
$5.49 - $8.79 $50,980 - $81,623
9,286 Added 468.75%
11,267 $64,000
Q2 2022

Jul 25, 2022

SELL
$5.33 - $8.18 $126,928 - $194,798
-23,814 Reduced 92.32%
1,981 $14,000
Q1 2022

May 02, 2022

SELL
$5.5 - $9.19 $6,484 - $10,835
-1,179 Reduced 4.37%
25,795 $186,000
Q4 2021

Jan 28, 2022

BUY
$7.67 - $44.59 $206,890 - $1.2 Million
26,974 New
26,974 $241,000

Others Institutions Holding AVIR

About Atea Pharmaceuticals, Inc.


  • Ticker AVIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,258,600
  • Market Cap $272M
  • Description
  • Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...
More about AVIR
Track This Portfolio

Track Allspring Global Investments Holdings, LLC Portfolio

Follow Allspring Global Investments Holdings, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allspring Global Investments Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Allspring Global Investments Holdings, LLC with notifications on news.